E. Worth

The Disposition of Saquinavir in Normal and P-glycoprotein Deficient Mice, Rats, and in Cultured Cells

C B Washington, Hugh Wiltshire, M Man et al. · Drug Metabolism and Disposition · 2000 · 89 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Biological Properties of the Angiotensin-Converting Enzyme Inhibitor Cilazapril

Ian L. Natoff, John Nixon, Robert J. Francis et al. · Journal of Cardiovascular Pharmacology · 1985 · 72 citations

Medicine, Medicinal Chemistry, Pharmacology +14

(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl-2′-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a Selective and Orally Active Inhibitor of Tumor Necrosis Factor-α Convertase

Gregory Beck, Gillian A. Bottomley, D. Bradshaw et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 52 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Metabolism of the calcium antagonist, mibefradil (POSICORTM, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man

Hugh Wiltshire, Blaine M. Sutton, G. Heeps et al. · Xenobiotica · 1997 · 26 citations

Medicine, Pharmacokinetics, Pharmacology +15

Metabolism of calcium antagonist Ro 40-5967: a case history of the use of diode-array u.v. spectroscopy and thermospray-mass spectrometry in the elucidation of a complex metabolic pathway

Hugh Wiltshire, Stephanie R. Harris, K. J. Prior et al. · Xenobiotica · 1992 · 17 citations

Life Sciences, Biochemistry, Pharmacology +17